Related references
Note: Only part of the references are listed.Mammalian galectins: Structure, carbohydrate specificity, and functions
E. M. Rapoport et al.
BIOCHEMISTRY-MOSCOW (2008)
The role of p53 tumor-suppressor protein in apoptosis and cancerogenesis
G. K. Maximov et al.
BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT (2008)
Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer
Maryse Lemaire et al.
BMC CANCER (2008)
Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells
F. Condorelli et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Apoptosis and non-apoptotic deaths in cancer development and treatment response
Elza C. de Bruin et al.
CANCER TREATMENT REVIEWS (2008)
Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor
Yang Wang et al.
CLINICAL CANCER RESEARCH (2008)
Deregulation of the Akt pathway in human cancer
Eriko Tokunaga et al.
CURRENT CANCER DRUG TARGETS (2008)
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
Jaclyn LoPiccolo et al.
DRUG RESISTANCE UPDATES (2008)
Bevacizumab for the treatment of advanced non-small-cell lung cancer
Christian Manegold
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Alemtuzumab for B-cell chronic lymphocytic leukemia
Tadeusz Robak
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids
Dario Barbone et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
To kill a tumor cell: the potential of proapoptotic receptor agonists
Avi Ashkenazi et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
Avi Ashkenazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
Anil Shanker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines
Antonino Neri et al.
LEUKEMIA & LYMPHOMA (2008)
The potential of histone deacetylase inhibitors for the treatment of multiple myeloma
H. Miles Prince et al.
LEUKEMIA & LYMPHOMA (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Caspases in apoptosis and beyond
J. Li et al.
ONCOGENE (2008)
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
Sanjeev Shangary et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
FLIP as an anti-cancer therapeutic target
Jin Kuk Yang
YONSEI MEDICAL JOURNAL (2008)
The apoptosome: Emerging insights and new potential targets for drug design
Marcello D'Amelio et al.
PHARMACEUTICAL RESEARCH (2008)
VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic
Richard J. Epstein
CANCER AND METASTASIS REVIEWS (2007)
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
Dylan Daniel et al.
BLOOD (2007)
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor - Related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2
Mitchell R. Smith et al.
CLINICAL CANCER RESEARCH (2007)
Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients
Gustave J. Ullenhag et al.
CLINICAL CANCER RESEARCH (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Targeting survivin in cancer therapy: fulfilled promises and open questions
Marzia Pennati et al.
CARCINOGENESIS (2007)
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma
Patricia Gomez-Bougie et al.
CANCER RESEARCH (2007)
Targeting TRAIL agonistic receptors for cancer therapy
Carmelo Carlo-Stella et al.
CLINICAL CANCER RESEARCH (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phosphorothioate oligonucleotides reduce mitochondrial outer membrane permeability to ADP
Wenzhi Tan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2007)
A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins
Jie Qin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Immunotoxin treatment of cancer
Ira Pastan et al.
ANNUAL REVIEW OF MEDICINE (2007)
MDM2 inhibitors for cancer therapy
Lyubomir T. Vassilev
TRENDS IN MOLECULAR MEDICINE (2007)
Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy
R. Kim et al.
CANCER GENE THERAPY (2007)
Pharmacokinetics of rituximab and its clinical use: Thought for the best use?
Guillaume Cartron et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand
Carmelo Carlo-Stella et al.
HUMAN GENE THERAPY (2006)
Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein
Jianyong Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Proteasome inhibitor drugs on the rise
Claudio A. P. Joazeiro et al.
CANCER RESEARCH (2006)
The hypoxic inducible stress response as a target for cancer drug discovery
Sarah J. Welsh et al.
SEMINARS IN ONCOLOGY (2006)
Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced sotid tumours
Stefan R. Vink et al.
RADIOTHERAPY AND ONCOLOGY (2006)
Alpha-fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-caspase interaction
Elena Dudich et al.
FEBS JOURNAL (2006)
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
AX Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors
N Amino et al.
CLINICAL CANCER RESEARCH (2006)
Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells
ZT Schafer et al.
CANCER RESEARCH (2006)
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib
K Sutheesophon et al.
ACTA HAEMATOLOGICA (2006)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
The Akt/PKB pathway: molecular target for cancer drug discovery
JQ Cheng et al.
ONCOGENE (2005)
AKT signaling in normal and malignant cells
JR Testa et al.
ONCOGENE (2005)
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-Cell malignancies
RJ Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
RJ Arceci et al.
BLOOD (2005)
Decitabine in acute myeloid leukemia
M Lübbert et al.
SEMINARS IN HEMATOLOGY (2005)
Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1
RI Feldman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Surface exposure of phosphatidylserine in pathological cells
RFA Zwaal et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
Apoptosis in the development and treatment of cancer
R Gerl et al.
CARCINOGENESIS (2005)
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
A Nebbioso et al.
NATURE MEDICINE (2005)
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
AP Mone et al.
BLOOD (2004)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay
HZ Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis
AE Greijer et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells
E Bremer et al.
NEOPLASIA (2004)
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt
L Yang et al.
CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
N Issaeva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Targeting the PI3K-Akt pathway in human cancer: Rationale and promise
J Luo et al.
CANCER CELL (2003)
Caspases: Keys in the ignition of cell death
JB Denault et al.
CHEMICAL REVIEWS (2002)
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
VJN Bykov et al.
CARCINOGENESIS (2002)
The BCL2 family: Regulators of the cellular life-or-death switch
S Cory et al.
NATURE REVIEWS CANCER (2002)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
NATURE REVIEWS CANCER (2002)
Death and anti-death: Tumour resistance to apoptosis
FH Igney et al.
NATURE REVIEWS CANCER (2002)
Fas receptor-mediated apoptosis: a clinical application?
T Timmer et al.
JOURNAL OF PATHOLOGY (2002)
FLICE-inhibitory proteins: Regulators of death receptor-mediated apoptosis
A Krueger et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
ASPP proteins specifically stimulate the apoptotic function of p53
Y Samuels-Lev et al.
MOLECULAR CELL (2001)
Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus
TS Griffith et al.
MOLECULAR THERAPY (2001)
Proliferation, cell cycle and apoptosis in cancer
GI Evan et al.
NATURE (2001)
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F Curnis et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
